[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559485":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":54,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Necmi Kadıoğlu Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stem Cell Application Group","EXPERIMENTAL","In this group, UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC\u002Fkg. The applications will be applied after kasai portoenterostomy.",[13],"Drug: Stem Cell",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","SHAM_COMPARATOR","In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to Biliary Atresia patients will continue to be administered.",[19],"Other: Control",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Stem Cell","UC-MSC transplantation will be administered twice to each patient in the study group via the hepatic artery: the first transplantation will be performed post-surgery at the beginning, and the second one will be performed 6 months later, with a dose of 1 million UC-MSC\u002Fkg.",[9],null,{"type":6,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"In this group, UC-MSC will not be administered. This group serves as a passive control. The standard treatments that are routinely provided to these patients will continue to be administered.",[15],[31],{"name":32,"affiliation":33,"role":34},"Mustafa Azizoglu, MD, PhD","Esenyurt State Hospital","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+905447448244","mdmazizoglu@gmail.com",[41],{"facility":33,"status":42,"city":43,"state":43,"zip":44,"country":45,"countryCode":26,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Istanbul","34340","Turkey (Türkiye)",{"type":47,"coordinates":48},"Point",[49,50],28.94966,41.01384,{"lat":50,"lon":49},[53],{"name":32,"role":37,"phone":38,"phoneExt":26,"email":39},{"type":34,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Mustafa Azizoğlu","Medical Doctor","100559485","stem-cell-applications-in-biliary-atresia-patients-100559485",false,"NCT06564740","Stem Cell Applications in Biliary Atresia Patients","Umbilical Cord Derived Mesenchymal Stem Cell (UC-MSC) Transplantation in Infants with Biliary Atresia: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Infants were diagnosed with liver cirrhosis due to biliary atresia following Kasai's operation.\n* The patients two months old or older and exhibited signs of cirrhosis after the procedure, including hepatomegaly, congestive splenomegaly, elevated liver enzymes, esophageal varices (confirmed by endoscopy), and cirrhosis (confirmed by liver biopsy).\n\nExclusion Criteria:\n\n* Epilepsy\n* Neurological disorders\n* Coagulation disorders\n* Diabetes\n* Syndromic type biliary atresia\n* Allergies to anesthetic agents\n* Severe health conditions such as cancer or failure of the heart, lungs, liver, or kidneys, active infections, and severe psychiatric disorders.","ALL","2 Months","18 Years",{"count":68,"type":69},64,"ESTIMATED","INTERVENTIONAL",[72],"NA","Recently, mesenchymal stem cell (MSC) transplantation has emerged as a promising treatment for liver cirrhosis in adults. Additionally, bone marrow-derived stem cell transplantation has shown success in treating children with biliary atresia (BA). This study aims to evaluate the efficacy of Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSC) therapy in BA through a multicentric randomized controlled trial.",[75,76,23],"Biliary Atresia","Fibrosis, Liver",[78,79,80],"biliary atresia","liver fibrosis","stem cell","2024-09-03",{"date":83,"type":84},"2024-09-19","ACTUAL",{"date":86,"type":84},"2024-06-01",{"date":88,"type":69},"2026-06-01",{"name":5,"class":6},1]